You are here: Industry Insights > Axitinib

News List

Clearside Biomedical Expands Patent Portfolio in the U.S. and Europe americanpharmaceuticalreview
August 27, 2020
Clearside Biomedical announced the recent issuance of three additional patents in the United States and Europe.
Avelumab + Axitinib Approved for Treatment of Renal Cell Carcinoma drugs
May 17, 2019
Avelumab + Axitinib Approved for Treatment of Renal Cell Carcinoma.
FDA Approves BAVENCIO® plus Axitinib Combination for Advanced Renal Cell Carcinoma americanpharmaceuticalreview
May 16, 2019
Merck and Pfizer announced the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) in combination with axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Keytruda/Inlyta combo shows significant survival benefit in kidney cancer trial pharmatimes
October 25, 2018
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS)...
Pfizer pulls plug on Inlyta trial pharmatimes
July 17, 2018
Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit in this setting.
Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery biospace
April 11, 2018
Pfizer today announced that the Independent Data Monitoring Committee of the Phase III ATLAS trial evaluated INLYTA® (axitinib) as an adjunct to high-risk patients with recurrent renal cell carcinoma (RCC) after renal cell carcinoma